Victory Capital Management Inc. acquired a new stake in Replimune Group, Inc. (NASDAQ:REPL - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 44,880 shares of the company's stock, valued at approximately $543,000. Victory Capital Management Inc. owned about 0.07% of Replimune Group as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors have also recently made changes to their positions in the stock. Erste Asset Management GmbH bought a new stake in Replimune Group during the 3rd quarter valued at $133,000. BNP Paribas Financial Markets raised its stake in shares of Replimune Group by 81.7% during the third quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock valued at $165,000 after acquiring an additional 6,748 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Replimune Group by 24.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock worth $198,000 after purchasing an additional 3,177 shares during the period. GSA Capital Partners LLP bought a new stake in shares of Replimune Group in the third quarter worth about $222,000. Finally, Intech Investment Management LLC purchased a new position in Replimune Group during the 3rd quarter valued at about $252,000. Hedge funds and other institutional investors own 92.53% of the company's stock.
Analyst Upgrades and Downgrades
A number of analysts recently commented on the company. JPMorgan Chase & Co. raised their price target on Replimune Group from $16.00 to $18.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. HC Wainwright lifted their target price on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. Jefferies Financial Group increased their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research note on Wednesday, December 4th. Finally, BMO Capital Markets lifted their price objective on Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday, January 22nd. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Replimune Group presently has an average rating of "Buy" and a consensus price target of $19.43.
View Our Latest Report on REPL
Replimune Group Stock Down 3.3 %
Shares of REPL traded down $0.36 on Tuesday, hitting $10.69. 557,439 shares of the stock traded hands, compared to its average volume of 842,165. The company has a market capitalization of $823.29 million, a PE ratio of -3.48 and a beta of 1.30. Replimune Group, Inc. has a one year low of $4.92 and a one year high of $17.00. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.43 and a current ratio of 11.43. The business has a 50 day simple moving average of $12.66 and a 200 day simple moving average of $12.16.
Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, equities analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.
About Replimune Group
(
Free Report)
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.
See Also
Before you consider Replimune Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Replimune Group wasn't on the list.
While Replimune Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
